PepGen (PEPG) News Today → Has Trump Finally Gone Too Far? (From Insiders Exposed) (Ad) Free PEPG Stock Alerts $14.01 +0.67 (+5.02%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHHS panel to vote in Nov. on DMD screening for newbornsmsn.com - May 9 at 9:16 PMBuy Rating on Sarepta Therapeutics Backed by Elevidys’s Market Expansion and FDA Approval Prospectsmarkets.businessinsider.com - May 2 at 12:41 PMOptimistic Outperform Rating on Sarepta Therapeutics Amid Strong Elevidys Demand and Potential Label Expansionmarkets.businessinsider.com - April 26 at 5:35 PMHedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and Moreinsidermonkey.com - April 12 at 3:01 PMPepGen Inc. (NASDAQ:PEPG) Sees Large Growth in Short Interestmarketbeat.com - April 1 at 3:48 PMPepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease Designationsmarketwatch.com - March 13 at 7:48 PMPepGen to Participate in Upcoming Investor Conferencesglobenewswire.com - March 13 at 4:05 PMPepGen Secures FDA's Orphan Drug, Rare Pediatric Disease Designations For PGN-EDO51markets.businessinsider.com - March 13 at 9:47 AMPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophyglobenewswire.com - March 13 at 7:00 AMStifel Nicolaus Reaffirms Their Buy Rating on PepGen Inc. (PEPG)markets.businessinsider.com - March 12 at 2:04 AMAdage Capital Partners GP L.L.C. Increases Position in PepGen Inc. (NASDAQ:PEPG)marketbeat.com - March 11 at 6:42 AMPepGen, Inc. (PEPG) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 9 at 3:32 PMWedbush Weighs in on PepGen Inc.'s FY2028 Earnings (NASDAQ:PEPG)marketbeat.com - March 8 at 7:36 AMPepGen (NASDAQ:PEPG) Price Target Lowered to $20.00 at Wedbushmarketbeat.com - March 7 at 8:43 AMFmr LLC Lowers Holdings in PepGen Inc. (NASDAQ:PEPG)marketbeat.com - March 7 at 4:39 AMPEPG Stock Earnings: PepGen Beats EPS for Q4 2023investorplace.com - March 7 at 1:01 AMPepGen's DMD therapy advances to phase 2 trial in the UKinvesting.com - March 6 at 4:40 PMPepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developmentsglobenewswire.com - March 6 at 4:01 PMPepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophyglobenewswire.com - March 4 at 7:00 AMRathbones Group PLC Makes New $315,000 Investment in PepGen Inc. (NASDAQ:PEPG)marketbeat.com - February 24 at 6:26 AMFDA grants fast track to PepGen’s DM1 treatmentmsn.com - February 21 at 4:25 PMPepGen Receives U.S. FDA Fast Track Designation For PGN-EDODM1 For The Treatment Of DM1markets.businessinsider.com - February 20 at 1:06 PMPepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1finance.yahoo.com - February 20 at 1:06 PMPepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1globenewswire.com - February 20 at 8:00 AMInsider Buying: Taking a Controlling Stake in a Struggling Retailer?247wallst.com - February 18 at 11:20 AMPepGen Inc. Secures Funding to Advance Research Programsmsn.com - February 8 at 3:34 PMPepGen Inc. Announces Pricing for Its Offeringmsn.com - February 8 at 10:34 AMPepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stocktmcnet.com - February 7 at 9:42 AMPepGen Stock Higher After Follow-on Offeringmarketwatch.com - February 7 at 9:42 AMPepGen soars on Sarepta Therapeutics' Duchenne drug phase 2 datamsn.com - February 6 at 7:54 AMPepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 datamarketbeat.com - February 6 at 6:05 AMTop 4 Health Care Stocks That May Crash This Quartermarkets.businessinsider.com - February 2 at 12:43 PMBuy Rating Affirmed for PepGen Inc. on Strong Prospects in DMD Treatment and Promising EDO Platformmarkets.businessinsider.com - January 31 at 4:52 PMPepGen stock soars after rival Sarepta reports data for DMD drugmsn.com - January 30 at 1:58 PMWedbush Reiterates "Outperform" Rating for PepGen (NASDAQ:PEPG)marketbeat.com - January 30 at 11:37 AMmarketbeat.com - January 30 at 10:56 AMPepGen: Long Road Aheadseekingalpha.com - January 20 at 10:11 PMDay One Announces Two New Appointments to Board of Directorsfinance.yahoo.com - January 17 at 9:55 AMMary Beth DeLena Joins PepGen as General Counsel and Secretaryfinance.yahoo.com - January 17 at 9:55 AMInstitutions own 24% of PepGen Inc. (NASDAQ:PEPG) shares but private equity firms control 54% of the companyfinance.yahoo.com - January 12 at 6:33 AMPepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skippingfinance.yahoo.com - January 8 at 8:10 AMPepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)finance.yahoo.com - December 18 at 1:05 PMWe Think PepGen (NASDAQ:PEPG) Needs To Drive Business Growth Carefullyfinance.yahoo.com - December 2 at 10:40 AMPepGen Announces Appointment of Howard Mayer, M.D. to Board of Directorsfinance.yahoo.com - November 15 at 12:15 PMPepGen Inc PEPGmorningstar.com - November 11 at 9:14 AMFein’s Buy Rating on Biogen: Leqembi’s Potential Growth and Market Penetrationmarkets.businessinsider.com - November 10 at 12:13 AMPepGen GAAP EPS of -$0.98msn.com - November 8 at 2:39 PMPepGen: Q3 Earnings Insightsbenzinga.com - November 8 at 9:39 AMPepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developmentsfinance.yahoo.com - November 8 at 9:39 AMAnalysts’ Top Healthcare Picks: Immuneering (IMRX), PepGen Inc. (PEPG)markets.businessinsider.com - October 17 at 2:34 PM Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address Collapse of the Petrodollar (Ad)The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason. In answer to this issue, we have released a Special Report to the public. PEPG Media Mentions By Week PEPG Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PEPG News Sentiment▼0.300.56▲Average Medical News Sentiment PEPG News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PEPG Articles This Week▼31▲PEPG Articles Average Week Get PepGen News Delivered to You Automatically Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Esperion Therapeutics News Revance Therapeutics News Acelyrin News Theravance Biopharma News Entrada Therapeutics News Neurogene News Lexicon Pharmaceuticals News Fulcrum Therapeutics News Korro Bio News Heron Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PEPG) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
